Cargando…

Outlook of IL-6 signaling blockade for COVID-19 pneumonia

In this review article, it is highlighted the implications of pleiotropic functions of interleukin-6 (IL-6) for one of the therapeutic options targeting for COVID-19. Moreover, it is discussed how real-world data and trials with IL-6 signaling blockade will be crucial in informing the development of...

Descripción completa

Detalles Bibliográficos
Autor principal:	Hashizume, Misato
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2020
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7533147/ https://www.ncbi.nlm.nih.gov/pubmed/33024459 http://dx.doi.org/10.1186/s41232-020-00134-7

Ejemplares similares

Respiratory Impairment Predicts Response to IL-1 and IL-6 Blockade in COVID-19 Patients With Severe Pneumonia and Hyper-Inflammation
por: Della-Torre, Emanuel, et al.
Publicado: (2021)

Multifactorial expression of IL-6 with update on COVID-19 and the therapeutic strategies of its blockade (Review)
por: Niculet, Elena, et al.
Publicado: (2021)

A myeloid program associated with COVID-19 severity is decreased by therapeutic blockade of IL-6 signaling
por: Hackney, Jason A., et al.
Publicado: (2023)

Translating IL-6 biology into effective treatments
por: Choy, Ernest H., et al.
Publicado: (2020)

The Roles of Interleukin-6 in the Pathogenesis of Rheumatoid Arthritis
por: Hashizume, Misato, et al.
Publicado: (2011)

IL-6 blockade for COVID-19: a global scientific call to arms
por: Murthy, Srinivas, et al.
Publicado: (2021)

Interleukin-6 signaling blockade treatment for cytokine release syndrome in COVID-19 (Review)
por: Chen, Jia-Jie, et al.
Publicado: (2021)

The importance of IL-6 blockade beyond the COVID-19 pandemic: Consideration for cancer care()
por: Iorio, Giuseppe Carlo, et al.
Publicado: (2020)

Implications of Interleukin-6 (IL-6)-blockade for severe COVID-19 infection in patients with Multiple Myeloma
por: Sgherza, Nicola, et al.
Publicado: (2021)

COVID-19 reinfection: Linked Possibilities and future outlook
por: Krishna, Ekta, et al.
Publicado: (2020)

An Outlook on Dental Practices to Avoid the Oral Transmission of COVID-19
por: Alsulami, Manal, et al.
Publicado: (2023)

Is IL-6 the Right Target in COVID-19 Severe Pneumonia?
por: Blot, Mathieu, et al.
Publicado: (2021)

Blockade of IL‐33 signalling attenuates osteoarthritis
por: He, Zengliang, et al.
Publicado: (2020)

The Homosexual Outlook
por: Tredgold, R. F.
Publicado: (1955)

Blockade of IL-6 signaling prevents paclitaxel-induced neuropathy in C57Bl/6 mice
por: Huehnchen, Petra, et al.
Publicado: (2020)

An updated overview of recent advances, challenges, and clinical considerations of IL-6 signaling blockade in severe coronavirus disease 2019 (COVID-19)
por: Elahi, Reza, et al.
Publicado: (2022)

An outlook on potential protein targets of COVID-19 as a druggable site
por: Noori, Rubia, et al.
Publicado: (2022)

Review and outlook of global energy use under the impact of COVID‐19
por: Zhang, Dongdong, et al.
Publicado: (2022)

Blockade of IL-6/IL-6R Signaling Attenuates Acute Antibody-Mediated Rejection in a Mouse Cardiac Transplantation Model
por: Ma, Maolin, et al.
Publicado: (2021)

Role of IP-10 to Predict Clinical Progression and Response to IL-6 Blockade With Sarilumab in Early COVID-19 Pneumonia. A Subanalysis of the SARICOR Clinical Trial
por: Trigo-Rodríguez, Marta, et al.
Publicado: (2023)

Clinical outcomes after IL-6 blockade in patients with COVID-19 and HIV: a case series
por: Minkove, Samuel J., et al.
Publicado: (2022)

Blockade of IL-23: What is in the Pipeline?
por: Parigi, Tommaso Lorenzo, et al.
Publicado: (2022)

Astrocytes revisited: concise historic outlook on glutamate homeostasis and signaling
por: Parpura, Vladimir, et al.
Publicado: (2012)

IL-6 signaling blockade increases inflammation but does not affect muscle function in the mdx mouse
por: Kostek, Matthew C, et al.
Publicado: (2012)

Corrigendum: Blockade of IL-6/IL-6R Signaling Attenuates Acute Antibody-Mediated Rejection in a Mouse Cardiac Transplantation Model
por: Ma, Maolin, et al.
Publicado: (2021)

The conundrum of interleukin-6 blockade in COVID-19
por: Campochiaro, Corrado, et al.
Publicado: (2020)

IL-6 Trans-Signaling via the Soluble IL-6 Receptor: Importance for the Pro-Inflammatory Activities of IL-6
por: Rose-John, Stefan
Publicado: (2012)

Interleukin-6 blockade with sarilumab in severe COVID-19 pneumonia with systemic hyperinflammation: an open-label cohort study
por: Della-Torre, Emanuel, et al.
Publicado: (2020)

Socio-economic impact of coronavirus disease 2019 (COVID-19) – An Indian outlook
por: Pillai, Dinesh Dhamodhar Mathevan, et al.
Publicado: (2020)

Revival of the heterologous prime‐boost technique in COVID‐19: An outlook from the history of outbreaks
por: Siddiqui, Amna, et al.
Publicado: (2022)

Genetic IL-6R variants and therapeutic inhibition of IL-6 receptor signalling in COVID-19
por: Garbers, Christoph, et al.
Publicado: (2021)

Mental Deficiency: The Changing Outlook
por: Tredgold, R. F.
Publicado: (1959)

Market outlook: post-COVID-19, what will change?
Publicado: (2020)

Outlook of various diagnostics and nanodiagnostic techniques for COVID-19
por: Preethi, Mosam, et al.
Publicado: (2022)

COVID and the outlook for emerging markets()
por: Eichengreen, Barry
Publicado: (2022)

Immunotherapy of COVID-19: Inside and Beyond IL-6 Signalling
por: Zizzo, Gaetano, et al.
Publicado: (2022)

IL-6 Blockade as a Therapeutic Approach for Duchenne Muscular Dystrophy
por: Mammen, Andrew L., et al.
Publicado: (2015)

Demystifying MOGAD and Double Seronegative NMOSD Further With IL-6 Blockade
por: Yong, Kok Pin, et al.
Publicado: (2021)

Outlook
por: Perkins, Donald Hill
Publicado: (1995)

Outlook
por: Glashow, Sheldon Lee
Publicado: (1991)

Cannot write session to /tmp/vufind_sessions/sess_kig8udfhval993hp94q9cks1qa